Disease relevance of Neurothekeoma

• Using a streptavidin-biotin-immunoperoxidase procedure, we examined the reactivity of 65 MM (46 conventional, 1 polypoid, 6 desmoplastic [DMM], and 12 metastatic), 21 neurofibromas, 1 neurofibrosarcoma, 10 schwannomas, 1 perineurioma, 2 neurothekeomas, and 14 blue and 26 other nevi for CD-68, HMB-45-defined antigen, S 100 and neurofilament protein [1].

High impact information on Neurothekeoma

• Microphthalmia transcription factor and NKI/C3 expression in cellular neurothekeoma [2].
• We studied a series of 11 cellular neurothekeomas using paraffin immunoperoxidase staining with microphthalmia transcription factor (Mitf), NKI/C3, and S-100 [2].
• In contrast, immunoreactivity to S-100 protein is only positive in 3 of 12 cases of cellular neurothekeoma [3].
• PGP9.5: a marker for cellular neurothekeoma [3].
• All cellular neurothekeomas failed to express S-100 protein, whereas the three myxomatous types were strongly positive for this marker [4].

Chemical compound and disease context of Neurothekeoma

• METHODS: Formalin-fixed, paraffin-embedded archival tissues were evaluated by immunohistochemistry using antibodies specific for S100A6 and PGP9.5 in 11 cases of neurothekeoma (seven cellular, four myxoid) [5].

Gene context of Neurothekeoma

• These results, such as the concomitant expressions of PGP9.5/S-100A6 and PG-M1/CD68 (KP-1), support the theory of multiple differentiation in cellular neurothekeomas [6].
• RESULTS: All 11 neurothekeoma cases were positive for S100A6 protein (four cases, weak/1+; seven cases, strong/2+), corresponding to 100% sensitivity [5].
• The significance of the expression of CD10 in this cellular neurothekeoma is unclear [6].

References